AML‐BFM Registry 2017

• Recording of all AML diseases in children and adolescents and their treatment in the participating centres of all participating countries
• Recording of genetic, molecular genetic and epigenetic characteristics of AML in children and adolescents
• Assessment of minimal residual disease (MRD) by means of morphology, immunophenotyping and molecular genetics
• Assessment of the frequency and kinetics of molecular relapse

The registry is intended to comprehensively record all children and adolescents with AML and their treatment as well as the cytogenetic, molecular genetic and epigenetic characteristics of AML in this age group. The response to standardised therapy can also provide important insights into the characterisation of AML. Furthermore, the frequency and kinetics of molecular recurrence during and after completion of intensive chemotherapy is being recorded, such as the MRD load in the peripheral blood, which is measured monthly.

Treatment recommendations

The registry serves exclusively to collect data. It does not provide explicit treatment recommendations. Patients are supposed to be treated according to the standardised treatment protocols.

• age from 0–17 years
• de novo AML, myelosarcoma, acute mixed lineage leukaemia / biphenotypic leukaemia (dominant myeloid according to WHO 2008) or
• AML as a second malignancy or
• transient leukaemia and myeloid leukaemia with trisomy 21 or
• relapsed/refractory AML in children and adolescents or
• "special" cases of AML-associated diseases after consultation and approval by the registry centre
• admission to an accredited paediatric oncology centre according to GBA resolution "Paediatric Oncology"
• availability of all necessary informed consent forms

• Lack of the patient’s and/or the legal guardian’s informed consent